ArticleBMC cancer2025
The diagnostic performance of a noninvasive urine-based methylation biomarkers Vimentin/POU4F2 to detect bladder carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBladder carcinoma (BC) is a malignant tumor that originates from the epithelial cells of the urinary system. Currently, the main diagnostic methods suffer from disadvantages including being invasive, having high costs, and low sensitivity and specificity. Therefore, there is an urgent need to develop a non-invasive, high-performance method for diagnosing BC. MATERIALS AND
methodsWe developed a urine DNA detection panel utilizing two methylation biomarkers for the diagnosis of BC. A total of 467 urine samples were collected from the First Affiliated Hospital of Anhui Medical University for DNA methylation analysis. The methylation levels of Vimentin and POU class 4 homeobox 2 gene (POU4F2) were analyzed in a training set of 306 urine samples (92 cases and 214 controls), and in an independent validation set of 161 urine samples (59 cases and 102 controls) using Real-Time PCR (RT-PCR).
resultsThe Vimentin/POU4F2 combined methylation panel achieved an AUC of 0.935 (95% CI: 0.889–0.981), with sensitivity, specificity, and accuracy of 86.44% (95% CI: 0.772–0.957), 96.08% (95% CI: 0.923–0.998), and 92.55% (95% CI: 0.886–0.965) for diagnosing BC. Notably, for patients with stage I and low-grade BC, the sensitivity was 90.00% for both. Additionally, it demonstrated specificities of 96.30% and 95.83% for patients with other urinary diseases and malignancies in other systems.
conclusionsOur study provides evidence that the two-gene methylation panel based on urine DNA detection demonstrates strong performance in diagnosing BC with high sensitivity and accuracy, offering a promising strategy for early screening and adjunctive diagnosis of BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.